logo-loader
RNS
viewGlaxoSmithKline PLC

Block listing Interim Review

/**/ sup{font-size:80%}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;} .n{size:595.3pt 841.9pt;margin:19.85pt 56.65pt 44.95pt 49.65pt;}div.n{}p.bk{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.bi{font-size:11.0pt;font-family:"Arial","sans-serif"}p.bl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}span.bf{font-size:11.0pt;font-family:"Arial","sans-serif"; font-variant:small-caps}table.bm{width:489.0pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.bd{width:49.86%;border:solid windowtext 1.0pt; padding:1.4pt 5.4pt 0cm 5.4pt}p.bn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm} td.bc{width:50.14%;border:solid windowtext 1.0pt; border-left:none;padding:1.4pt 5.4pt 0cm 5.4pt}td.bb{width:49.86%;border:solid windowtext 1.0pt; border-top:none;padding:1.4pt 5.4pt 0cm 5.4pt}td.ba{width:50.14%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:1.4pt 5.4pt 0cm 5.4pt}td.az{width:37.18%;border:solid windowtext 1.0pt; border-top:none;padding:1.4pt 5.4pt 0cm 5.4pt}td.ay{width:12.68%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:1.4pt 5.4pt 0cm 5.4pt}td.ax{width:20.1%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:1.4pt 5.4pt 0cm 5.4pt}td.aw{width:7.34%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:1.4pt 5.4pt 0cm 5.4pt}td.av{width:22.7%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:1.4pt 5.4pt 0cm 5.4pt}span.au{font-size:18.0pt;font-family:"Arial","sans-serif"}td.at{border:none} td.ar{width:49.84%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.aq{width:50.16%;border:solid windowtext 1.0pt;border-left: none;padding:0cm 5.4pt 0cm 5.4pt}td.ap{width:49.84%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.ao{width:50.16%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.an{width:49.86%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.am{width:50.14%;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}tr.aj{height:37.95pt}td.al{width:49.86%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:37.95pt}td.ak{width:50.14%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:37.95pt}tr.ad{height:27.9pt} td.ai{width:37.18%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:27.9pt}td.ah{width:12.68%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:27.9pt}td.ag{width:20.1%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:27.9pt}td.af{width:7.34%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:27.9pt}td.ae{width:22.7%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:27.9pt}td.ac{width:49.86%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.ab{width:50.14%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}tr.y{height:54.3pt}td.aa{width:49.86%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:54.3pt}td.z{width:50.14%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:54.3pt} tr.v{height:40.65pt}td.x{width:49.86%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:40.65pt}td.w{width:50.14%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:40.65pt}br.u{page-break-before:always}td.t{width:37.18%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.s{width:12.68%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.r{width:20.1%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.q{width:7.34%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.p{width:22.7%;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.bo{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt; margin-left:0cm} /**/
RNS Number : 7382U
GlaxoSmithKline PLC
26 November 2019
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 26 November 2019

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2019

To:

31 October 2019

Balance of unallotted securities under scheme(s) from previous return:

153,724

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

153,724

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 26 November 2019

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares

Period of return:

From:

1 May 2019

To:

31 October 2019

Balance of unallotted securities under scheme(s) from previous return:

1,265,008

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

429,913

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

835,095

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 26 November 2019

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - ADS

Period of return:

From:

1 May 2019

To:

31 October 2019

Balance of unallotted securities under scheme(s) from previous return:

5,911,296

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

519,880

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

5,391,416

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 26 November 2019

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2019

To:

31 October 2019

Balance of unallotted securities under scheme(s) from previous return:

2,326,896

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

181,084

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

2,145,812

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRKMMZMDVFGLZM

Quick facts: GlaxoSmithKline PLC

Price: 1819.2

Market: LSE
Market Cap: £90.82 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Director/PDMR Shareholding

1 week, 1 day ago

Director/PDMR Shareholding

1 week, 2 days ago

Director/PDMR Shareholding

1 week, 2 days ago

Director/PDMR Shareholding

1 week, 3 days ago

Director/PDMR Shareholding

1 week, 3 days ago

Director/PDMR Shareholding

1 week, 3 days ago

Director/PDMR Shareholding

1 week, 3 days ago